GB
Publicaties op Oncologisch.com
Eerstelijns Camizestrant for Emerging ESR1-Mutated Gevorderd Breast Cancer.
Abemaciclib Plus Fulvestrant in Gevorderd Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Fase...
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Tri...
Serum TK1 bij HR+/HER2- mammacarcinoom onder CDK4/6-remmer: analyse
T-DXd versus physician's choice bij HER2-positief mammacarcinoom: DESTINY-Breast02 fase III
T-DXd versus T-DM1 bij HER2-positief mammacarcinoom: DESTINY-Breast03 OS